vizet - search results

European Union - Italian - EMA (European Medicines Agency)

amgevita

amgen europe b.v. - adalimumab - arthritis, psoriatic; colitis, ulcerative; arthritis, juvenile rheumatoid; spondylitis, ankylosing; psoriasis; crohn disease; arthritis, rheumatoid - immunosoppressori - rheumatoid arthritis amgevita in combination with methotrexate, is indicated for: , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. il trattamento di grave, attiva e progressiva artrite reumatoide negli adulti non precedentemente trattati con metotressato. , amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. amgevita riduce il tasso di progressione del danno articolare misurato da x-ray e migliora la funzione fisica, quando somministrato in combinazione con metotressato. juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (dmards). amgevita può essere somministrato come monoterapia in caso di intolleranza al metotressato o quando il trattamento continuato con metotressato è inappropriato (per l'efficacia in monoterapia vedere la sezione 5. adalimumab non è stato studiato in pazienti di età inferiore a 2 anni. enthesitis-related arthritis amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5. axial spondyloarthritis ankylosing spondylitis (as) amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. axial spondyloarthritis without radiographic evidence of as amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of as but with objective signs of inflammation by elevated crp and/or mri, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs. psoriatic arthritis amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. amgevita riduce il tasso di progressione del danno articolare periferico come misurato da raggi x in pazienti con poliarticolare simmetrica sottotipi della malattia (vedere la sezione 5. 1) e migliora la funzione fisica. psoriasis amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. paediatric plaque psoriasis amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. hidradenitis suppurativa (hs) amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic hs therapy (see sections 5. 1 e 5. crohn’s disease amgevita is indicated for treatment of moderately to severely active crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies. paediatric crohn's disease amgevita is indicated for the treatment of moderately to severely active crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. ulcerative colitis amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-mp) or azathioprine (aza), or who are intolerant to or have medical contraindications for such therapies. uveitis amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. paediatric uveitis amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

vitrakvi 25 mg capsule

bayer (schweiz) ag - larotrectinibum - capsule - larotrectinibum 25 mg ut larotrectinibi sulfas, kapselhülle: gelatina, e 171, drucktinte: lacca, e 132, e 171, propylenglycolum, dimeticonum 1000, pro capsula. - behandlung von soliden tumoren mit ntrk (neurotrophe tyrosin-rezeptor-kinase)-genfusion - synthetika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

vitrakvi 100 mg capsule

bayer (schweiz) ag - larotrectinibum - capsule - larotrectinibum 100 mg ut larotrectinibi sulfas, kapselhülle: gelatina, e 171, drucktinte: lacca, e 132, e 171, propylenglycolum, dimeticonum 1000, pro capsula. - behandlung von soliden tumoren mit ntrk (neurotrophe tyrosin-rezeptor-kinase)-genfusion - synthetika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

vitrakvi 20 mg/ml soluzione orale

bayer (schweiz) ag - larotrectinibum - soluzione orale - larotrectinibum 20 mg ut larotrectinibi sulfas, acidum citricum, maltodextrinum, triethylis citras, aromatica (erdbeer) cum alcohol benzylicus, propylenglycolum, hydroxypropylbetadexum 174.6 mg, e 211 2 mg, natrii citras dihydricus, sucralosum, aqua purificata, ad solutionem pro 1 ml corresp. natrium max. 4.17 mg. - behandlung von soliden tumoren mit ntrk (neutrophe tyrosin-rezeptor-kinase)-genfusion - synthetika

Switzerland - Italian - Swissmedic (Swiss Agency for Therapeutic Products)

vita gerin geistlich kapseln

geistlich pharma ag - retinoli palmitas, cholecalciferolum, int-rac-alfa-tocopherylis acetas, thiamini nitras, riboflavinum, pyridoxini hydrochloridum, cyanocobalaminum, nicotinamidum, dexpanthenolum, acidum ascorbicum, calcii hydrogenophosphas, calcii magnesii fytas trihydricus, ferro, cuprum, manganum, acidum oroticum anhydricum, cholini hydrogenotartras, rutina trihydricum - kapseln - vitamina: retinoli palmitas 10000 u. i., cholecalciferolum 400 u. i. int-rac-alfa-tocopherylis acetas 15 mg, thiamini nitras 10 mg, riboflavinum 3 mg, pyridoxini hydrochloridum 5 mg, cyanocobalaminum 5 µg, nicotinamidum 10 mg, dexpanthenolum 10 mg, acidum ascorbicum 70 mg, mineralia: calcii hydrogenophosphas 85 mg, calcii magnesii fytas trihydricus 50 mg, ferro 10 mg ut ferrosi fumaras, cuprum 1 mg ut cupri di zolfo, manganum 0,5 mg ut mangani zolfo monohydricus, in particolare: deanoli orotas e magnesii orotas dihydricus corrisp. acidum oroticum anhydricum 100 mg, cholini hydrogenotartras 50 mg rutina trihydricum 10 mg, excipiens pro il capsula. - vitamina - und mineralstoffpräparat bei mangelzuständen im alter - synthetika